🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. ALX-0061

    Sanofi Pasteur

    Lupus Erythematosus, Systemic

    phase 2 mab completed

    1 trial

  2. AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT)

    Minoryx Therapeutics S.L.

    CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD)

    phase 2 other active

    1 trial

  3. AP31969, AP31969, The placebo tablets contain the same excipient as in the active IMP, but without AP31969. All tablet strengths containing AP31969 as well as placebo tablets are visually identical., AP31969, AP31969

    Lacuna Pharma Pty Ltd

    Atrial fibrillation

    phase 2 small molecule active

    1 trial

  4. APD811

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 2 small molecule completed

    1 trial

  5. APG777

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    3 trials

  6. APG777, Placebo

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  7. APO010

    Allarity Therapeutics

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  8. APR-246

    Aprea Therapeutics

    Myelodysplastic Syndrome

    phase 2 small molecule completed

    1 trial

  9. APR-246

    Aprea Therapeutics

    Myelodysplastic Syndrome With Gene Mutation

    phase 2 small molecule active

    1 trial

  10. APR-246

    Aprea Therapeutics

    Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

    phase 2 small molecule completed

    1 trial

  11. APR-246

    Aprea Therapeutics

    Acute Myeloid Leukemia or Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  12. APR-246

    Aprea Therapeutics

    High-grade Serous Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  13. APR-246

    Aprea Therapeutics

    Melanoma

    phase 2 small molecule terminated

    1 trial

  14. APR-246 (eprenetapopt) + Acalabrutinib in CLL

    Aprea Therapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  15. APR-246 (eprenetapopt) + Pembrolizumab

    Aprea Therapeutics

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  16. ARCT-021

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab terminated

    1 trial

  17. ARCT-021 Dose 1

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab completed

    1 trial

  18. ARCT-021 single dose priming

    Arcturus Therapeutics Holdings

    Covid19

    phase 2 mab terminated

    1 trial

  19. ARCT-032

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 small molecule active

    2 trials

  20. ARCT-165

    Arcturus Therapeutics Holdings

    COVID-19

    phase 2 mab completed

    1 trial

  21. ARCT-810

    Arcturus Therapeutics Holdings

    OTC Deficiency

    phase 2 mab active

    1 trial

  22. ARCT-810

    Arcturus Therapeutics Holdings

    Ornithine Transcarbamylase Deficiency

    phase 2 mab completed

    3 trials

  23. ARD-101

    Ark Therapeutics

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial

  24. ARD-101

    Ark Therapeutics

    Bariatric Surgery

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources